Search
Philadelphia, PA Paid Clinical Trials
A listing of 1864 clinical trials in Philadelphia, PA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1669 - 1680 of 1864
There are currently 1864 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Defining Treatment Outcomes and Genetic Architecture in Idiopathic Toe Walking*
Recruiting
To compare and contrast the clinical, gait and parent-reported outcomes following either non-operative (casting) or operative treatment for children with idiopathic toe walking (ITW) and determine whether there are specific genes associated with ITW.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/23/2024
Locations: Shriners Hospitals for Children, Philadelphia, Pennsylvania
Conditions: Idiopathic Toe Walking
A Partnered Evaluation to Improve the Identification and Management of Functional Impairment and Frailty Among Older Veterans in Primary Care Settings
Recruiting
Maintaining functional status, or the ability to perform daily activities, is central to older adults' quality of life, health, and ability to remain independent. Identifying functional impairments is essential for clinicians to provide optimal care to older adults, and on a population level, understanding function can help anticipate service needs. Yet uptake of standardized measurement of functional status into patient care has been slow and inconsistent due to the burden posed by current tool... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/22/2024
Locations: Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania
Conditions: Functional Impairment, Frailty
Decoding and Modulating Affective Brain States
Recruiting
Generating personalized brain signatures of negative emotion along with personalized brain stimulation protocols to disrupt these patterns. We plan to use fMRI and muscle activity data to determine negative affect maps for each participant. We will then try a variety of patterned repetitive transcranial magnetic stimulation sequences while recording fMRI which will be the basis of two sessions of 3-day individualized brain stimulation designed to reduce negative affect.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/19/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Rumination, Major Depressive Disorder, Anxiety
Li-Fraumeni Syndrome/TP53 Biobank
Recruiting
Li-Fraumeni Syndrome (LFS) and Li-Fraumeni-like (LFL) Syndrome are cancer predisposition syndromes due to germline aberrations in the TP53 gene. Patients with classical LFS have a lifetime malignancy risk between 80-90%, with 21% of those cancers occurring by the age of 15 years. There are established guidelines for screening patients with LFS that have led to earlier detection and treatment of cancer in this population. There are a number of important issues facing patients identified to have g... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/18/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania +1 locations
Conditions: Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome
Human Learning of New Structured Information Across Time and Sleep
Recruiting
Acting adaptively requires quickly picking up on structure in the environment and storing the acquired knowledge for effective future use. Dominant theories of the hippocampus have focused on its ability to encode individual snapshots of experience, but the investigators and others have found evidence that it is also crucial for finding structure across experiences. The mechanisms of this essential form of learning have not been established. The investigators have developed a neural network mode... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
07/18/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Learning, Humans, Consolidation, Sleep
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Recruiting
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2024
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
Supportive Understanding and Patient-centered Partnership for Optimizing Renal Treatment
Recruiting
Black and Hispanic people face higher risks of chronic kidney disease (CKD) but have unequal access to the highest-quality kidney care. Black adults with CKD face 1.5 times higher hospitalization risks than non-Black adults with CKD. Once reaching end stage kidney disease (ESKD), Black patients are half as likely to receive a transplant and are often excluded from home dialysis. Structural racism creates complex barriers to optimal CKD care, providing an explanation for these findings. The Penn... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Penn Medicine, Philadelphia, Pennsylvania
Conditions: Chronic Kidney Diseases, Racism, Systemic, Trauma, Psychological
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
Recruiting
The primary objective of this study is to determine the longer-term (6 months) effect of CPAP therapy on change in 24-hour mean blood pressure (24hMBP) in OSA subjects with the excessively sleepy symptom subtype.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/15/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Obstructive Sleep Apnea
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Recruiting
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Universiy of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations
Recruiting
The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. The ePVA is digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. The study aims to advance the science of cancer care delivery by testing the effectivenes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Head and Neck Cancer
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
Recruiting
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Recruiting
This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania
Conditions: Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
1669 - 1680 of 1864